<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004262</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01400</org_study_id>
    <secondary_id>99H0239</secondary_id>
    <secondary_id>CDR0000067517</secondary_id>
    <secondary_id>NCI-T99-0041</secondary_id>
    <secondary_id>OSU-9976</secondary_id>
    <secondary_id>OSU-99H0239</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00004262</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme</brief_title>
  <official_title>PHASE I TRIAL OF GADOLINIUM TEXAPHYRIN (PCI -0120) AS A RADIOSENSITIZER DURING STEREOTACTIC RADIOSURGERY BOOST FOR GLIOBLASTOMA MULTIFORME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of radiation therapy and gadolinium texaphyrin in&#xD;
      treating patients who have supratentorial glioblastoma multiforme. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make the&#xD;
      tumor cells more sensitive to radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the frequency and grade of toxicity of gadolinium texaphyrin as a&#xD;
      radiosensitizer at two dose levels in patients with supratentorial glioblastoma multiforme&#xD;
      undergoing stereotactic radiosurgery.&#xD;
&#xD;
      II. Compare the tumor, normal brain, and plasma concentrations of this drug regimen to 1.5&#xD;
      and 8 Tesla MRI images in this patient population.&#xD;
&#xD;
      III. Determine if the 8 Tesla images provide more data than the 1.5 Tesla images in terms of&#xD;
      the radiosensitizing drug distribution in the tumor in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days&#xD;
      a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive&#xD;
      gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery.&#xD;
      Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive&#xD;
      gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior&#xD;
      to stereotactic radiosurgery.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gadolinium texaphyrin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for 3 months, and then every 3 months for 5 years or until&#xD;
      death.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 12-18 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT), as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 2.0</measure>
    <time_frame>At the time of stereotactic radiosurgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of gadolinium in tumor, normal brain, and plasma by plasma-atomic emission spectroscopy and liquid chromatography with mass spectrometry</measure>
    <time_frame>At baseline, at 48 hours, and at 2 weeks post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
    <other_name>surgery, conventional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
    <other_name>gadolinium texaphyrin</other_name>
    <other_name>Gd (III) Texaphryin</other_name>
    <other_name>Gd-Tex</other_name>
    <other_name>PCI-0120</other_name>
    <other_name>Xcytrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets</description>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>spectroscopy</intervention_name>
    <description>Undergo plasma-atomic emission spectroscopy (DCP-AES)</description>
    <arm_group_label>Treatment (motexafin gadolinium, radiotherapy, radiosurgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed supratentorial glioblastoma multiforme by stereotactic&#xD;
             biopsy, open biopsy, or resection&#xD;
&#xD;
          -  Maximum diameter of the tumor mass must be no greater than 4 cm in any dimension,&#xD;
             including following debulking surgery&#xD;
&#xD;
          -  Tumor must be at least 1.0 cm from the optic chiasm and brainstem&#xD;
&#xD;
          -  No oligodendrogliomas, meningiomas, or grade I, II, or III astrocytomas&#xD;
&#xD;
          -  No infratentorial tumors&#xD;
&#xD;
          -  No multifocal glioblastoma multiforme&#xD;
&#xD;
          -  Tumor enhances on MRI&#xD;
&#xD;
          -  Must have visible tumor on postoperative MRI following surgical resection&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT no greater than 60 U/L&#xD;
&#xD;
          -  Creatinine no greater than 1.3 mg/dL&#xD;
&#xD;
          -  Blood urea nitrogen no greater than 24 mg/dL&#xD;
&#xD;
          -  Neurological function status 0-3&#xD;
&#xD;
          -  No evidence of neuropathy&#xD;
&#xD;
          -  No glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  No known history of porphyria&#xD;
&#xD;
          -  History of prior malignancies allowed&#xD;
&#xD;
          -  HIV positive status allowed&#xD;
&#xD;
          -  No medical contraindication to MRI imaging (i.e., pacemaker, aneurysm clip, or&#xD;
             nonsecure metal fragment close to a critical structure)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and during study&#xD;
&#xD;
          -  At least 6 weeks since prior chemotherapy&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
          -  No prior radiotherapy to the brain or upper neck&#xD;
&#xD;
          -  No greater than 5 weeks since prior surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Grecula</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

